희귀질환 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 의약품 유형별, 질환별, 투여 경로별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

Orphan Drugs Market Summary

The global orphan drugs market size was valued at USD 220.1 billion in 2025 and is projected to grow from USD 238.1 billion in 2026 to USD 434.9 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The industry is growing due to the increasing focus on developing treatments for rare diseases, supported by favorable regulatory policies and continuous advances in medical research.

Many rare diseases still have limited or no approved treatment options, creating a strong need for new therapies. Incentives such as market exclusivity, tax benefits, fee reductions, and faster regulatory review encourage pharmaceutical and biotechnology companies to invest in orphan drug development. Progress in genetic research, biologics, gene therapy, and cell therapy has improved the development of targeted treatments for several rare conditions. In addition, better disease awareness, wider use of genetic testing, patient advocacy efforts, and expanded screening programs are helping improve early diagnosis and access to treatment. At the same time, companies continue to face challenges related to high research and development costs, small patient populations, complex manufacturing processes, and pricing pressures. These factors continue to shape investment decisions and competition in the orphan drugs market.

Global Orphan Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global orphan drugs market report based on drug type, disease type, route of administration, distribution channel, and region:

• Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Small Molecule Drugs
• Conventional Biologics
• Gene Therapies
• Cell Therapies
• Others
• Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Rare Genetic & Inherited Disorders
• Rare Cancers
• Rare Congenital & Developmental Disorders
• Rare Autoimmune & Immune-Mediated Disorders
• Rare Infectious Diseases Rare Acquired Disorders
• Rare Acquired Disorders
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Intrathecal
• Intraocular / Ophthalmic
• Inhalation
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Mail-Order / Online Pharmacies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Disease Type
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Orphan Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Orphan Drugs Market: Drug Type Business Analysis

• 4.1. Drug Type Market Share, 2025 & 2033
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Billion)
• 4.4. Small Molecule Drugs
  • 4.4.1. Small Molecule Drugs Market, 2021 - 2033 (USD Billion)
• 4.5. Conventional Biologics
  • 4.5.1. Conventional Biologics Market, 2021 - 2033 (USD Billion)
• 4.6. Gene Therapies
  • 4.6.1. Gene Therapies Market, 2021 - 2033 (USD Billion)
• 4.7. Cell Therapies
  • 4.7.1. Cell Therapies Market, 2021 - 2033 (USD Billion)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Orphan Drugs Market: Disease Type Business Analysis

• 5.1. Disease Type Market Share, 2025 & 2033
• 5.2. Disease Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
• 5.4. Rare Genetic & Inherited Disorders
  • 5.4.1. Rare Genetic & Inherited Disorders Market, 2021 - 2033 (USD Billion)
• 5.5. Rare Cancers
  • 5.5.1. Rare Cancers Market, 2021 - 2033 (USD Billion)
• 5.6. Rare Congenital & Developmental Disorders
  • 5.6.1. Rare Congenital & Developmental Disorders Market, 2021 - 2033 (USD Billion)
• 5.7. Rare Autoimmune & Immune-Mediated Disorders
  • 5.7.1. Rare Autoimmune & Immune-Mediated Disorders Market, 2021 - 2033 (USD Billion)
• 5.8. Rare Infectious Diseases
  • 5.8.1. Rare Infectious Diseases Market, 2021 - 2033 (USD Billion)
• 5.9. Rare Acquired Disorders
  • 5.9.1. Rare Acquired Disorders Market, 2021 - 2033 (USD Billion)
• 5.10. Others
  • 5.10.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Orphan Drugs Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
• 6.4. Oral
  • 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
• 6.5. Intravenous
  • 6.5.1. Intravenous Market, 2021 - 2033 (USD Billion)
• 6.6. Subcutaneous
  • 6.6.1. Subcutaneous Market, 2021 - 2033 (USD Billion)
• 6.7. Intramuscular
  • 6.7.1. Intramuscular Market, 2021 - 2033 (USD Billion)
• 6.8. Intrathecal
  • 6.8.1. Intrathecal Market, 2021 - 2033 (USD Billion)
• 6.9. Intraocular / Ophthalmic
  • 6.9.1. Intraocular / Ophthalmic Market, 2021 - 2033 (USD Billion)
• 6.10. Inhalation
  • 6.10.1. Inhalation Market, 2021 - 2033 (USD Billion)
• 6.11. Others
  • 6.11.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Orphan Drugs Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.5. Specialty Pharmacies
  • 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.6. Retail Pharmacies
  • 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.7. Mail-Order / Online Pharmacies
  • 7.7.1. Mail-Order / Online Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.8. Others
  • 7.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Orphan Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Orphan Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Orphan Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Johnson & Johnson
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. AstraZeneca
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Roche
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Novartis
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Vertex Pharmaceuticals
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Sanofi
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Amgen
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Merck & Co.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Bristol Myers Squibb
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Pfizer
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives